SREBF1 and glioblastoma: Consistent with the literature reports, GlioVis analysis (Bowman et al, 2017) showed that SREBF1 is more expressed in the most aggressive GBM subtypes (mesenchymal and classical) and correlates with patient survival (Fig S3C and D).